UroGen Pharma Ltd. (LON:0XOD)
London
· Delayed Price · Currency is GBP · Price in USD 14.20
-0.28 (-1.94%)
At close: Jul 11, 2025
UroGen Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 91.87 | 90.4 | 82.71 | 64.36 | 48.04 | 11.8 | Upgrade
| |
Revenue Growth (YoY) | 8.98% | 9.29% | 28.52% | 33.96% | 307.17% | 65450.00% | Upgrade
|
Cost of Revenue | 9.48 | 8.88 | 9.36 | 7.65 | 5.16 | 1.01 | Upgrade
|
Gross Profit | 82.39 | 81.52 | 73.35 | 56.7 | 42.89 | 10.79 | Upgrade
|
Selling, General & Admin | 127.72 | 120.05 | 93.27 | 82.84 | 87.54 | 90.22 | Upgrade
|
Research & Development | 61.52 | 57.15 | 45.61 | 52.91 | 47.64 | 40.71 | Upgrade
|
Operating Expenses | 189.24 | 177.2 | 138.89 | 135.74 | 135.18 | 130.93 | Upgrade
|
Operating Income | -106.86 | -95.68 | -65.54 | -79.04 | -92.29 | -120.14 | Upgrade
|
Interest Expense | -14.14 | -12.52 | -14.72 | -8.44 | - | - | Upgrade
|
Interest & Investment Income | 9.31 | 8.9 | 2.64 | 0.94 | 0.37 | 1.99 | Upgrade
|
Other Non Operating Income (Expenses) | -22.47 | -23.64 | -20.71 | -21.49 | -17.44 | -0.36 | Upgrade
|
EBT Excluding Unusual Items | -134.16 | -122.94 | -98.32 | -108.03 | -109.37 | -118.51 | Upgrade
|
Other Unusual Items | -1.1 | -1.1 | - | - | - | -6.6 | Upgrade
|
Pretax Income | -135.26 | -124.04 | -98.32 | -108.03 | -109.37 | -125.11 | Upgrade
|
Income Tax Expense | 3.17 | 2.83 | 3.92 | 1.76 | 1.45 | 3.37 | Upgrade
|
Net Income | -138.43 | -126.87 | -102.24 | -109.78 | -110.82 | -128.48 | Upgrade
|
Net Income to Common | -138.43 | -126.87 | -102.24 | -109.78 | -110.82 | -128.48 | Upgrade
|
Shares Outstanding (Basic) | 45 | 43 | 29 | 23 | 22 | 22 | Upgrade
|
Shares Outstanding (Diluted) | 45 | 43 | 29 | 23 | 22 | 22 | Upgrade
|
Shares Change (YoY) | 40.86% | 48.70% | 26.43% | 2.05% | 2.60% | 6.10% | Upgrade
|
EPS (Basic) | -3.04 | -2.96 | -3.55 | -4.81 | -4.96 | -5.90 | Upgrade
|
EPS (Diluted) | -3.04 | -2.96 | -3.55 | -4.81 | -4.96 | -5.90 | Upgrade
|
Free Cash Flow | -107.39 | -97.06 | -76.57 | -87.81 | -85.64 | -107.1 | Upgrade
|
Free Cash Flow Per Share | -2.36 | -2.26 | -2.66 | -3.85 | -3.83 | -4.92 | Upgrade
|
Gross Margin | 89.68% | 90.18% | 88.68% | 88.11% | 89.27% | 91.45% | Upgrade
|
Operating Margin | -116.31% | -105.84% | -79.23% | -122.82% | -192.11% | -1018.21% | Upgrade
|
Profit Margin | -150.68% | -140.35% | -123.61% | -170.58% | -230.67% | -1088.94% | Upgrade
|
Free Cash Flow Margin | -116.90% | -107.37% | -92.57% | -136.45% | -178.27% | -907.71% | Upgrade
|
EBITDA | -106.58 | -95.35 | -64.73 | -78.12 | -91.46 | -119.72 | Upgrade
|
EBITDA Margin | -116.01% | -105.48% | -78.26% | -121.38% | -190.38% | - | Upgrade
|
D&A For EBITDA | 0.28 | 0.33 | 0.8 | 0.92 | 0.83 | 0.42 | Upgrade
|
EBIT | -106.86 | -95.68 | -65.54 | -79.04 | -92.29 | -120.14 | Upgrade
|
EBIT Margin | -116.31% | -105.84% | -79.23% | -122.82% | -192.11% | - | Upgrade
|
Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.